Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2401 in newly diagnosed pediatric DIPG
NCT03178032Phase 1Completed
- Sponsor
- Universidad de Navarra
- Start
- May 2017
- Primary completion
- Jan 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5-D24RGD in diffuse intrinsic pontine glioma (DIPG), sponsored by Universidad de Navarra. Primary endpoint: Safety, tolerability and toxicity of DNX-2401 at 12 weeks. Started May 2017; status: completed.
02
Drugs
Ad5-D24RGD
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT03178032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178032.